{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:46:08Z","timestamp":1794271568509,"version":"4.9.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Drug Delivery"],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1080\/10717544.2018.1551442","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T05:21:02Z","timestamp":1549948862000},"page":"98-106","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":183,"title":["ENHANZE\n                    <sup>\u00ae<\/sup>\n                    drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20"],"prefix":"10.1080","volume":"26","author":[{"given":"Kenneth W.","family":"Locke","sequence":"first","affiliation":[{"name":"Halozyme Therapeutics, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Maneval","sequence":"additional","affiliation":[{"name":"Halozyme Therapeutics, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"LaBarre","sequence":"additional","affiliation":[{"name":"Halozyme Therapeutics, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"key":"CIT0001","unstructured":"Alexion Pharmaceuticals I. (2017). Alexion and Halozyme Enter License Agreement for ENHANZE Technology. Available at: http:\/\/files.shareholder.com\/downloads\/ALXN\/6264479688x0x966094\/4E5A51B2-4A6E-4C45-83C1-1F8B8373B8C0\/ALXN_News_2017_12_7_General.pdf [last accessed 7 Sep 2018]."},{"key":"CIT0002","unstructured":"Alexion Pharmaceuticals I. (2018). Alexion development programs. Available at: http:\/\/alexion.com\/research-development\/development-programs [last accessed 19 Nov 2018]."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00004-1"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1949.00900050638012"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(98)00204-3"},{"key":"CIT0006","unstructured":"Baxter BioScience. (2014). HyQvia Blood Products Advisory Committee Meeting. Available at: https:\/\/wayback.archive-it.org\/7993\/20170406182957\/https:\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/BloodProductsAdvisoryCommittee\/UCM407013.pdf [last accessed September 2018]."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.05.027"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.4236\/abcr.2013.24022"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1038\/144977b0"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1021\/bi700382g"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.838.838"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/S0945-053X(01)00171-8"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0b013e31822860d9"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0945-053X(01)00172-X"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.573"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1999.14.5"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1517\/14712590903490382"},{"key":"CIT0020","first-page":"6","volume":"99","author":"Duran-Reynals F","year":"1928","journal-title":"Comptes Rendu Hebdomadaire de S\u00e9ances et M\u00e9moires de la Soci\u00e9t\u00e9 deBiologie"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1084\/jem.58.4.451"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.12.013"},{"key":"CIT0023","unstructured":"European Medicines Agency. (2013a). HyQvia EPAR Public Assessment Report. Available at: https:\/\/www.ema.europa.eu\/documents\/assessment-report\/hyqvia-epar-public-assessment-report_en.pdf [last accessed 19 Nov 2018]."},{"key":"CIT0024","unstructured":"European Medicines Agency. (2013b). HyQvia EPAR summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002491\/WC500143851.pdf [last accessed 31 May 2018]."},{"key":"CIT0025","unstructured":"European Medicines Agency. (2018a). DARZALEX summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/darzalex-epar-product-information_en.pdf [last accessed 19 Nov 2018]."},{"key":"CIT0026","unstructured":"European Medicines Agency. (2018b). Herceptin summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000278\/WC500074922.pdf [last accessed 25 May 2018]."},{"key":"CIT0027","unstructured":"European Medicines Agency. (2018c). MabThera summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000165\/WC500025821.pdf [last accessed 31 May 2018]."},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.427"},{"key":"CIT0029","unstructured":"Garrun D. (2013). Breaking barriers \u2013 the potential of subcutaneous drug delivery. Available at: https:\/\/www.drugdevelopment-technology.com\/features\/featurehalozyme-roche-subcutaneous-drug-delivery-platform\/ [last accessed Nov 13]."},{"key":"CIT0030","unstructured":"Great Ormond Street Hospital. (2017). Immunoglobulin infusions: intravenous and subcutaneous. Available at: https:\/\/www.gosh.nhs.uk\/health-professionals\/clinical-guidelines\/immunoglobulin-infusions-intravenous-and-subcutaneous#Rationale [last accessed Nov 15]."},{"key":"CIT0031","unstructured":"Halozyme Therapeutics Inc. (2018). FDA accepts biologics license application for subcutaneous formulation of herceptin. Available at: https:\/\/www.halozyme.com\/investors\/news-releases\/news-release-details\/2018\/FDA-Accepts-Biologics-License-Application-For-Subcutaneous-Formulation-Of-Herceptin\/default.aspx [last accessed 13 Aug 2018]."},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu524"},{"key":"CIT0033","first-page":"9","volume":"30","author":"Kang DW","year":"2013","journal-title":"Controll Release Newsl"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.125.5.1157"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.173583"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0808"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0115"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.023"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu364"},{"key":"CIT0041","unstructured":"Roche Canada. (2018a). Pr HERCEPTIN\n                      \u00ae\n                      SC product monograph. Available at: http:\/\/www.rochecanada.com\/content\/dam\/roche_canada\/en_CA\/documents\/Research\/ClinicalTrialsForms\/Products\/ConsumerInformation\/MonographsandPublicAdvisories\/Herceptin\/HerceptinSC_PM_E.pdf [last accessed Sep 2018]."},{"key":"CIT0042","unstructured":"Roche Canada. (2018b). Pr RITUXAN\n                      \u00ae\n                      SC product monograph. Available at: http:\/\/www.rochecanada.com\/content\/dam\/roche_canada\/en_CA\/documents\/Research\/ClinicalTrialsForms\/Products\/ConsumerInformation\/MonographsandPublicAdvisories\/RituxanSC\/RituxanSC_PM_E.pdf [last accessed 10 August 2018]."},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9782-0"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.914033"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2631"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00192"},{"key":"CIT0048","first-page":"1","volume":"12","author":"Silverstein SM","year":"2012","journal-title":"J Appl Res"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.09.011"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1021\/cr050247k"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.fl.25.010193.000245"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.03.009"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.03.010"},{"key":"CIT0054","unstructured":"U.S. Food and Drug Administration. (2003). United States Food and Drug Administration clinical review of NDA 21-640 (Vitrase\n                      \u00ae\n                      ). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-640_Vitrase_Medr.pdf [last accessed 31 May 2018]."},{"key":"CIT0055","unstructured":"U.S. Food and Drug Administration. (2005). HYLENEX prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021859s009lbl.pdf [last accessed 15 May 2018]."},{"key":"CIT0056","unstructured":"U.S. Food and Drug Administration. (2012). September 12, 2014 Approval Letter - HYQVIA. Available at: http:\/\/wayback.archive-it.org\/7993\/20170723025727\/https:\/www.fda.gov\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/ucm414148.htm [last accessed 19 Nov 2018]."},{"key":"CIT0057","unstructured":"U.S. Food and Drug Administration. (2014). HYQVIA prescribing information. 2014. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM414440.pdf [last accessed 15 Nov 2018]."},{"key":"CIT0058","unstructured":"U.S. Food and Drug Administration. (2017a). ODAC briefing document rituximab and hyaluronidase. Available at: https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM548659.pdf [last accessed 15 May 2018]."},{"key":"CIT0059","unstructured":"U.S. Food and Drug Administration. (2017b). RITUXAN HYCELA FDA approval. Available at: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm564235.htm [last accessed 7 May 2018]."},{"key":"CIT0060","unstructured":"U.S. Food and Drug Administration. (2017c). RITUXAN HYCELA prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761064s000lbl.pdf [last accessed 31 May 2018]."},{"key":"CIT0061","unstructured":"U.S. Food and Drug Administration. (2017b). Rituximab and hyaluronidase injection, for subcutaneous use (rituximab SC). Available at: https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM551240.pdf [last accessed 11\/07\/18]."},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.4158\/EP11297.RA"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2009.0013"},{"key":"CIT0064","volume-title":"Nonclinical studies to assess possible effects of antibodies to rHuPH20 on the endogenous counterpart","author":"Veneziale RW","year":"2014"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9740-x"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.34"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12519"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0066"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0298-x"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"CIT0071","unstructured":"World Health Organization. (2003). WHO Guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products. Available at: http:\/\/www.who.int\/biologicals\/publications\/en\/whotse2003.pdf?ua=1&ua=1 [last accessed 31 May 2018]."},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1177\/0091270012436560"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAN.0000292572.70387.17"}],"updated-by":[{"DOI":"10.1080\/10717544.2019.1594569","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000}}],"container-title":["Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10717544.2018.1551442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10717544.2018.1551442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T12:41:07Z","timestamp":1657111267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10717544.2018.1551442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"alternative-id":["10.1080\/10717544.2018.1551442"],"URL":"https:\/\/doi.org\/10.1080\/10717544.2018.1551442","relation":{},"ISSN":["1071-7544","1521-0464"],"issn-type":[{"value":"1071-7544","type":"print"},{"value":"1521-0464","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}